Alembic Pharmaceuticals gains 3% on zero observations from USFDA

USFDA inspected Vadodara facility between August 12, 2019, to August 20, 2019, for Bioequivalence Bioanalytical and Bioequivalence Clinical

Shares of Alembic Pharmaceuticals added 3 percent intraday on August 21 after the company received no observation from the US Food and Drug Administration (USFDA) for its Vadodara facility

The facility was inspected between August 12 and August 20 for bioequivalence bioanalytical and bioequivalence clinical.

They were issued Form 483s at the end of the inspection.

The share had touched its 52-week high of Rs 664 on September 27, 2018, and a 52-week low of Rs 435.10 on June 21, 2019.

Currently, it is trading 21.84 percent below its 52-week high and 19.28 percent above its 52-week low

Alembic Pharmaceuticals was quoting at Rs 519.00, up to Rs 8.65, or 1.69 percent.

For More Information Contact us @9644405057 or visit @Call Option and Put Option